Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Cure Ventures is a life sciences venture capital firm founded in 2021 and based in Boston, Massachusetts. The firm focuses on investing in the formation of new companies centered around groundbreaking curative technologies. Cure Ventures emphasizes a collaborative approach with entrepreneurs, aiming to develop therapeutics that address life-altering diseases.
As of now, Cure Ventures manages a portfolio of 12 companies, primarily in the biotech and healthcare sectors. The firm employs a team of experienced professionals, including co-founders Richard Lim, David Fallace, and Lou Tartaglia, who bring diverse expertise to the table. Their investment strategy is designed to de-risk scientific endeavors and enhance the probability of success for their portfolio companies.
Cure Ventures specializes in early-stage investments in the life sciences sector, particularly in biotechnology and healthcare. Their investment strategy is built on three key tenets: a seed funding model aimed at de-risking scientific endeavors, genetic validation to enhance the probability of success, and the involvement of embedded Cure operators to support day-to-day decision-making alongside founders.
The firm primarily invests in de novo company formation, focusing on innovative therapeutic solutions that address significant medical needs. Cure Ventures targets companies at various stages, including seed, Series A, and growth equity, with a geographic focus on North America. They seek founders who are passionate about their mission and are committed to developing transformative solutions in the life sciences.
Cure Ventures has a diverse portfolio of 12 companies, each focused on innovative therapeutic solutions. Notable portfolio companies include:
William Amsbaugh, M.S. - CTO and Partner. William has extensive experience in the life sciences sector, focusing on therapeutic development and operational strategy.
Milenko Cicmil, Ph.D. - Venture Partner. Milenko brings a strong background in scientific research and venture capital, having worked with various biotech startups.
Richard Lim, M.B.A. - Co-founder and Managing Partner. Richard has a proven track record in venture capital and has led multiple successful investments in the life sciences.
David Fallace, J.D., M.B.A. - Co-founder and Managing Partner. David combines legal expertise with business acumen, focusing on strategic investments in healthcare.
Lou Tartaglia, Ph.D. - Co-founder and Managing Partner. Lou has a deep understanding of drug development and has been instrumental in guiding portfolio companies through clinical trials.
To pitch Cure Ventures, founders should use the contact form available on their website at curevc.com. It is essential to include a comprehensive pitch deck that outlines the business model, scientific validation, and team qualifications. Response times may vary, but founders can expect to hear back within a few weeks.
Warm introductions are preferred, as they can facilitate a more favorable review of the pitch.
In 2023, Cure Ventures has actively expanded its portfolio, adding several innovative companies focused on life sciences. Notable recent investments include Aevum Therapeutics and Clasp Therapeutics, both of which are developing groundbreaking therapeutic solutions.
The firm continues to emphasize its commitment to addressing life-altering diseases through advanced technologies. Cure Ventures has also engaged in community outreach initiatives, partnering with organizations like Sightsavers and MiracleFeet to promote health equity.
What are Cure Ventures' investment criteria?
Cure Ventures focuses on early-stage investments in the life sciences sector, particularly in biotechnology and healthcare. They look for companies that are developing innovative therapeutic solutions and have a strong scientific foundation.
How can I apply or pitch to Cure Ventures?
Founders can pitch Cure Ventures through their website at curevc.com. It is recommended to include a detailed overview of the business model, scientific validation, and the team’s background in the pitch deck.
What makes Cure Ventures different from other VCs?
Cure Ventures emphasizes a collaborative approach with embedded operators who support portfolio companies in day-to-day decision-making. This hands-on involvement helps de-risk scientific endeavors and enhances the probability of success.
What is the geographic scope of Cure Ventures?
The firm primarily focuses on investments in North America, targeting companies that are innovating in the life sciences sector.
What is the typical check size for investments?
Cure Ventures invests at various stages, including seed, Series A, and growth equity, but specific check sizes are not publicly disclosed.
What kind of post-investment involvement can founders expect?
Cure Ventures provides operational support through embedded operators, who work closely with founders to guide the development of their companies and ensure alignment with strategic goals.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.